Advanced search in Research products
Research products
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
Include:
The following results are related to COVID-19. Are you interested to view more results? Visit OpenAIRE - Explore.
4 Research products, page 1 of 1

  • COVID-19
  • Other research products
  • National Institutes of Health
  • US
  • English
  • COVID-19

Relevance
arrow_drop_down
  • Other research product . Other ORP type . 2021
    Open Access English

    The attached compressed file package supplements our research article. It comprises SARS-CoV-2 variant timemaps SVG files for 2020 and 2021, updated with data submitted to GISAID as of February 10th 2021 (inclusive). It is a snapshot of the webpage hosting these maps (https://bcgsc.github.io/SARS2) on that day and includes the script and single nucleotide variation (SNV) report files used to generate these and could be used by anyone to generate additional and custom interactive SVG maps. The frequently updated and comprehensive SARS-CoV-2 genome SNV reports (https://www.bcgsc.ca/downloads/btl/SARS-CoV-2/mutations) represent a wealth of variant information that could be mined to gain further insights into the rapid SARS-CoV-2 coronavirus evolution in human hosts.

  • Other research product . Other ORP type . 2021
    Open Access English
    Authors: 
    Warren, Rene; Birol, Inanc;
    Publisher: Zenodo
    Project: NIH | De Novo Assembly Tools: R... (2R01HG007182-04A1)

    As year 2020 came to a close, several new strains have been reported for the SARS-CoV-2 coronavirus, the agent responsible for the COVID-19 pandemic that has afflicted us all this past year. However, it is difficult to comprehend the scale, in sequence space, geographical location and time, at which SARS-CoV-2 mutates and evolves in its human hosts. To get an appreciation for the rapid evolution of the coronavirus, we built interactive scalable vector graphics (SVG) maps that show daily nucleotide variations in genomes from the six most populated continents compared to that of the initial, ground-zero SARS-CoV-2 isolate sequenced at the beginning of the year. The attached compressed file package comprises SARS-CoV-2 mutation timemaps for 2020 and 2021, updated with data submitted to GISAID (gisaid.org) as of January 25th 2021 (inclusive). It is a snapshot of the webpage hosting these maps (https://bcgsc.github.io/SARS2) on that day.

  • Other research product . Other ORP type . 2021
    Open Access English
    Authors: 
    Warren, Rene; Birol, Inanc;
    Publisher: Zenodo
    Project: NIH | De Novo Assembly Tools: R... (2R01HG007182-04A1)

    As the year 2020 came to a close, several new strains have been reported for the SARS-CoV-2 coronavirus, the agent responsible for the COVID-19 pandemic that has afflicted us all this past year. However, it is difficult to comprehend the scale, in sequence space, geographical location and time, at which SARS-CoV-2 mutates and evolves in its human hosts. To get an appreciation for the rapid evolution of the coronavirus, we built interactive scalable vector graphics (SVG) maps that show daily nucleotide variations in genomes from the six most populated continents compared to that of the initial, ground-zero SARS-CoV-2 isolate sequenced at the beginning of the year. The attached compressed file package comprises SARS-CoV-2 mutation timemaps SVG files for 2020 and 2021, updated with data submitted to GISAID as of February 5th 2021 (inclusive). It is a snapshot of the webpage hosting these maps (https://bcgsc.github.io/SARS2) on that day and includes the script and single nucleotide variation (SNV) report files used to generate these and could be used by anyone to generate additional and custom interactive SVG maps. It supplements our F1000research article. The frequently updated and comprehensive SARS-CoV-2 genome SNV reports (https://www.bcgsc.ca/downloads/btl/SARS-CoV-2/mutations) represent a wealth of information that could be mined to gain further insights into the rapid SARS-CoV-2 coronavirus evolution in human hosts.

  • Open Access English
    Authors: 
    Cummings, Matthew J et al.;
    Project: NIH | Phenotyping sepsis in Uga... (5F32AI147528-02), NIH | Clinical and Translationa... (2UL1TR001873-06)

    Background: Nearly 30,000 patients with coronavirus disease-2019 (COVID-19) have been hospitalized in New York City as of April 14th, 2020. Data on the epidemiology, clinical course, and outcomes of critically ill patients with COVID-19 in this setting are needed. Methods: We prospectively collected clinical, biomarker, and treatment data on critically ill adults with laboratory-confirmed-COVID-19 admitted to two hospitals in northern Manhattan between March 2nd and April 1st, 2020. The primary outcome was in-hospital mortality. Secondary outcomes included frequency and duration of invasive mechanical ventilation, frequency of vasopressor use and renal-replacement-therapy, and time to clinical deterioration following hospital admission. The relationship between clinical risk factors, biomarkers, and in-hospital mortality was modeled using Cox-proportional-hazards regression. Each patient had at least 14 days of observation. Results: Of 1,150 adults hospitalized with COVID-19 during the study period, 257 (22%) were critically ill. The median age was 62 years (interquartile range [IQR] 51-72); 170 (66%) were male. Two-hundred twelve (82%) had at least one chronic illness, the most common of which were hypertension (63%; 162/257) and diabetes mellitus (36%; 92/257). One-hundred-thirty-eight patients (54%) were obese, and 13 (5%) were healthcare workers. As of April 14th, 2020, in-hospital mortality was 33% (86/257); 47% (122/257) of patients remained hospitalized. Two-hundred-one (79%) patients received invasive mechanical ventilation (median 13 days [IQR 9-17]), and 54% (138/257) and 29% (75/257) required vasopressors and renal-replacement-therapy, respectively. The median time to clinical deterioration following hospital admission was 3 days (IQR 1-6). Older age, hypertension, chronic lung disease, and higher concentrations of interleukin-6 and d-dimer at admission were independently associated with in-hospital mortality. Conclusions: Critical illness among patients hospitalized with COVID-19 in New York City is common and associated with a high frequency of invasive mechanical ventilation, extra-pulmonary organ dysfunction, and substantial in-hospital mortality.

Advanced search in Research products
Research products
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
Include:
The following results are related to COVID-19. Are you interested to view more results? Visit OpenAIRE - Explore.
4 Research products, page 1 of 1
  • Other research product . Other ORP type . 2021
    Open Access English

    The attached compressed file package supplements our research article. It comprises SARS-CoV-2 variant timemaps SVG files for 2020 and 2021, updated with data submitted to GISAID as of February 10th 2021 (inclusive). It is a snapshot of the webpage hosting these maps (https://bcgsc.github.io/SARS2) on that day and includes the script and single nucleotide variation (SNV) report files used to generate these and could be used by anyone to generate additional and custom interactive SVG maps. The frequently updated and comprehensive SARS-CoV-2 genome SNV reports (https://www.bcgsc.ca/downloads/btl/SARS-CoV-2/mutations) represent a wealth of variant information that could be mined to gain further insights into the rapid SARS-CoV-2 coronavirus evolution in human hosts.

  • Other research product . Other ORP type . 2021
    Open Access English
    Authors: 
    Warren, Rene; Birol, Inanc;
    Publisher: Zenodo
    Project: NIH | De Novo Assembly Tools: R... (2R01HG007182-04A1)

    As year 2020 came to a close, several new strains have been reported for the SARS-CoV-2 coronavirus, the agent responsible for the COVID-19 pandemic that has afflicted us all this past year. However, it is difficult to comprehend the scale, in sequence space, geographical location and time, at which SARS-CoV-2 mutates and evolves in its human hosts. To get an appreciation for the rapid evolution of the coronavirus, we built interactive scalable vector graphics (SVG) maps that show daily nucleotide variations in genomes from the six most populated continents compared to that of the initial, ground-zero SARS-CoV-2 isolate sequenced at the beginning of the year. The attached compressed file package comprises SARS-CoV-2 mutation timemaps for 2020 and 2021, updated with data submitted to GISAID (gisaid.org) as of January 25th 2021 (inclusive). It is a snapshot of the webpage hosting these maps (https://bcgsc.github.io/SARS2) on that day.

  • Other research product . Other ORP type . 2021
    Open Access English
    Authors: 
    Warren, Rene; Birol, Inanc;
    Publisher: Zenodo
    Project: NIH | De Novo Assembly Tools: R... (2R01HG007182-04A1)

    As the year 2020 came to a close, several new strains have been reported for the SARS-CoV-2 coronavirus, the agent responsible for the COVID-19 pandemic that has afflicted us all this past year. However, it is difficult to comprehend the scale, in sequence space, geographical location and time, at which SARS-CoV-2 mutates and evolves in its human hosts. To get an appreciation for the rapid evolution of the coronavirus, we built interactive scalable vector graphics (SVG) maps that show daily nucleotide variations in genomes from the six most populated continents compared to that of the initial, ground-zero SARS-CoV-2 isolate sequenced at the beginning of the year. The attached compressed file package comprises SARS-CoV-2 mutation timemaps SVG files for 2020 and 2021, updated with data submitted to GISAID as of February 5th 2021 (inclusive). It is a snapshot of the webpage hosting these maps (https://bcgsc.github.io/SARS2) on that day and includes the script and single nucleotide variation (SNV) report files used to generate these and could be used by anyone to generate additional and custom interactive SVG maps. It supplements our F1000research article. The frequently updated and comprehensive SARS-CoV-2 genome SNV reports (https://www.bcgsc.ca/downloads/btl/SARS-CoV-2/mutations) represent a wealth of information that could be mined to gain further insights into the rapid SARS-CoV-2 coronavirus evolution in human hosts.

  • Open Access English
    Authors: 
    Cummings, Matthew J et al.;
    Project: NIH | Phenotyping sepsis in Uga... (5F32AI147528-02), NIH | Clinical and Translationa... (2UL1TR001873-06)

    Background: Nearly 30,000 patients with coronavirus disease-2019 (COVID-19) have been hospitalized in New York City as of April 14th, 2020. Data on the epidemiology, clinical course, and outcomes of critically ill patients with COVID-19 in this setting are needed. Methods: We prospectively collected clinical, biomarker, and treatment data on critically ill adults with laboratory-confirmed-COVID-19 admitted to two hospitals in northern Manhattan between March 2nd and April 1st, 2020. The primary outcome was in-hospital mortality. Secondary outcomes included frequency and duration of invasive mechanical ventilation, frequency of vasopressor use and renal-replacement-therapy, and time to clinical deterioration following hospital admission. The relationship between clinical risk factors, biomarkers, and in-hospital mortality was modeled using Cox-proportional-hazards regression. Each patient had at least 14 days of observation. Results: Of 1,150 adults hospitalized with COVID-19 during the study period, 257 (22%) were critically ill. The median age was 62 years (interquartile range [IQR] 51-72); 170 (66%) were male. Two-hundred twelve (82%) had at least one chronic illness, the most common of which were hypertension (63%; 162/257) and diabetes mellitus (36%; 92/257). One-hundred-thirty-eight patients (54%) were obese, and 13 (5%) were healthcare workers. As of April 14th, 2020, in-hospital mortality was 33% (86/257); 47% (122/257) of patients remained hospitalized. Two-hundred-one (79%) patients received invasive mechanical ventilation (median 13 days [IQR 9-17]), and 54% (138/257) and 29% (75/257) required vasopressors and renal-replacement-therapy, respectively. The median time to clinical deterioration following hospital admission was 3 days (IQR 1-6). Older age, hypertension, chronic lung disease, and higher concentrations of interleukin-6 and d-dimer at admission were independently associated with in-hospital mortality. Conclusions: Critical illness among patients hospitalized with COVID-19 in New York City is common and associated with a high frequency of invasive mechanical ventilation, extra-pulmonary organ dysfunction, and substantial in-hospital mortality.